- Home
- BBIO
as 11-21-2024 12:31pm EST
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, acoramidis (AG10), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 4.9B | IPO Year: | 2019 |
| Target Price: | $46.92 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.62 - $44.32 | Next Earning Date: | 11-12-2024 |
| Revenue: | $217,765,000 | Revenue Growth: | 2209.77% |
| Revenue Growth (this year): | 3690.39% | Revenue Growth (next year): | -39.26% |
Stock Insider Trading Activity of BridgeBio Pharma Inc. (BBIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KKR Genetic Disorder L.P. | BBIO | 10% Owner | Sep 13 '24 | Sell | $25.75 | 5,800,000 | $149,350,000.00 | 25,260,971 |
Latest BridgeBio Pharma Inc. News
BBIO Breaking Stock News: Dive into BBIO Ticker-Specific Updates for Smart Investing
Benzinga
2 days ago
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
Simply Wall St.
2 days ago
The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically
GlobeNewswire
3 days ago
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
GlobeNewswire
3 days ago
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
Simply Wall St.
7 days ago
BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Morningstar Research
9 days ago
Analyst Report: BridgeBio Pharma, Inc.
Zacks
9 days ago
BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates
MT Newswires
9 days ago
BridgeBio Pharma's Q3 Loss Narrows, Revenue Declines
Compare BBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BBIO BridgeBio Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.